Market capitalization | PLN3.47b |
Enterprise Value | PLN4.03b |
P/E (TTM) P/E ratio | 20.86 |
EV/FCF (TTM) EV/FCF | 27.23 |
EV/Sales (TTM) EV/Sales | 0.33 |
P/S ratio (TTM) P/S ratio | 0.29 |
P/B ratio (TTM) P/B ratio | 3.30 |
Dividend yield | 1.81% |
Last dividend (FY23) | PLN14.50 |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
3 Analysts have issued a Neuca forecast:
3 Analysts have issued a Neuca forecast:
Jun '24 |
+/-
%
|
||
Revenue | 12,125 12,125 |
4%
4%
|
|
Gross Profit | 1,386 1,386 |
4%
4%
|
|
EBITDA | 387 387 |
20%
20%
|
EBIT (Operating Income) EBIT | 269 269 |
25%
25%
|
Net Profit | 165 165 |
53%
53%
|
In millions PLN.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NEUCA SA engages in the wholesale of pharmaceutical products. It operates through the following segments: Pharmaceutical Wholesale; Own Brands; and Outpatient Care Clinics, Clinical Trials, and Telemedicine. The Pharmaceutical Wholesale segment provides medical products for pharmacies. The Own Brands segment comprises market launching of pharmaceutical products under own brand. The Outpatient Care Clinics, Clinical Trials, and Telemedicine segment activities include general medical practice, clinical trials, and telemedicine. The company was founded by Kazimierz Michal Herba in 1990 and is headquartered in Torun, Poland.
Head office | Poland |
CEO | Piotr Sucharski |
Employees | 4,633 |
Founded | 1990 |
Website | www.neuca.pl |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.